Summary: Effects of Prednisolone Therapy on Blood Sugar Levels in Type 1 Diabetic Patients Using an Insulin Pump
Prednisolone, an intermediate-acting glucocorticoid, can significantly increase blood sugar levels in patients with type 1 diabetes mellitus (T1DM), including those managed with continuous subcutaneous insulin infusion (CSII). The rise in glucose tends to develop gradually after morning dosing, reaches a peak in the afternoon or evening, and may persist until the following morning.
Key Effects:
- Marked Hyperglycaemia: Prednisolone therapy may increase total daily insulin requirements by 30–70%, with considerable individual variability.
- Risk of Diabetic Ketoacidosis (DKA): Steroid-induced insulin resistance can precipitate DKA if insulin adjustments are not adequately made.
- Prolonged Hyperglycaemic Impact: Glucose elevation can persist beyond the day of prednisolone administration, often extending into the next day.
Insulin Pump Considerations:
- Frequent Monitoring: Intensified glucose monitoring is essential, as insulin needs may fluctuate rapidly.
- Basal Rate Adjustments: Temporary increases in basal rates or separate basal profiles may help manage the extended hyperglycaemic effect.
- Bolus Dosing: Enhanced rapid-acting correction boluses at or after prednisolone administration can counter postprandial spikes.
- Caution for Hypoglycaemia: Dose titration should be gradual and iterative, as T1DM patients are more prone to hypoglycaemia when prednisolone is tapered.
- Individualisation: The response is highly variable; insulin adjustments should reflect the prednisolone dose and concurrent patient factors.
Summary Guidance:
- Monitor capillary glucose closely (before meals, at bedtime, and potentially overnight).
- Consider increasing total daily insulin dose by ~10% for 20 mg PE, 20% for 40 mg, and 30% for 60 mg prednisolone equivalents, with careful titration.
- Collaborate with the diabetes care team to create a flexible pump profile for steroid therapy periods.